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Roger M. Nitsch and Christoph Hock have founded Neurodegenerative Diseases in 2004, and, thanks to their own and the editorial board's scientific expertise and untiring efforts, within a short time this journal has become a most lively and thriving meeting place in a fascinating and extremely promising subdiscipline of neuroscience. It is here where up-to-date research on neurobiological mechanisms is disseminated, offering an ever better understanding of Alzheimer (AD) and Parkinson disease, monogenetic autosomal disorders such as Huntington disease (HD), and many more disorders of the nervous system.
It is a great privilege to succeed as editor-in-chief the founding editors of this journal beginning in 2018, and I very much look forward to continue, supported by its experienced editorial board, its tradition of rapid publication of outstanding novel scientific studies.
Newly invited associate editors represent innovative methodological approaches in a dynamically expanding field, and it is based on their frontline expertise that Neurodegenerative Diseases will be able to evaluate, accept, and introduce to the scientific community the most convincing research methodologies and findings in brain studies.
Considering the development of disease-modifying therapeutic interventions for neurodegenerative brain disorders as a major goal of research, novel insights into brain changes prior to the manifestation of clinical syndromes are most promising. A better understanding of pathological sequences and neurobiological mechanisms implicated in these very early "preclinical" disease stages is regarded to lay open cellular vulnerability factors as a major factor of the etiology and pathogenesis of neurodegenerative disorders including AD [1, 2] , Parkinson [3] , amyotrophic lateral sclerosis [4] [5] [6] , and HD [7] . The identification of the relevant pathology in individuals at a point in time early enough for administering diseasemodifying therapy before irreversible neurodegenerative brain damage has commenced may represent a particular challenge for clinical research trials [8] . Recently published, encouraging first results of antibody-based therapy in AD [9] underline the potential of early and pathology-specific intervention, but also the need for improving diagnostic capabilities for detecting clinically inconspicuous individuals at increased risk.
A few hints at the research foci and most recent findings of colleagues who have followed our invitation to form the new team of Associate Editors of Neurodegen-
erative Diseases may suffice here to evidence our emphasis on bringing together a broadly based expertise that is able both to stimulate new conceptual and methodological approaches in the field and to attract pertinent findings to be published in our journal.
Thematically, Neurodegenerative Diseases will certainly continue to focus on the investigation of molecular mechanisms and basic biology. Recent work by Magdalini Polymenidou and her group at the University of Zurich points to a central role of functional and dynamic polymerization of the protein TDP-43 as a precondition of its pathological aggregation in amyotrophic lateral sclerosis, and possibly also its self-perpetuating, prionlike properties [10] [11] [12] . Wenzhen Duan is an expert in single gene mutations and autosomal dominant disorders at Johns Hopkins University [13] [14] [15] . Her own and her team's research has resulted in the hypothesis that expansion mutations as observable in HD may also have an etiological role in more frequent psychiatric diseases [16, 17] , allowing for novel therapeutic approaches [18] . Gene therapy aimed at single pathological targets, as performed by Janine Reichenbach and her team at the University of Zurich [19] [20] [21] , might thus attain therapeutic relevance beyond the initially targeted monogenetic disorder. Rodent models play a fundamental role to test novel mechanistic hypotheses as well as the resulting therapeutic interventions. Jan Klohs, from the Swiss Federal Institutes of Technology (ETH) and the University of Zurich, has demonstrated the potential of preclinical imaging for the determination of neurodegenerative and vascular pathology in various experimental settings [22] [23] [24] .
A novel thematic focus of the Journal Neurodegenerative Diseases shall be the translation of laboratory findings to clinical research. To this effect, the state-of-the-art implementation of clinical research methodology and the establishment of informative biomarkers will play a decisive role. Adam Brickman, from Columbia University, is an expert in this emerging research field, and recent work of him and his team has substantially contributed to better understand the role of white matter pathology in AD [25, 26] and the interplay between vascular disease and AD pathology [27, 28] . Considering the complexity of the clinical phenotype observable during the progression of neurodegenerative syndromes, interactive effects between genetic determination and environmental factors might be accountable [29, 30] . Here, biological phenotypes of increased risk may provide information on genetic variation associated with sporadic AD and other neurodegenerative disorders [31] [32] [33] . Stephan Ripke is an expert in statistical genetics at Harvard Medical School and Charité Universitaetsmedizin Berlin. His work and methodological input were vital for the recent progress in the characterization of genetic signatures of frequent psychiatric disorders including polygenetic effects and copy number variation [34] [35] [36] [37] [38] , which might also be informative for a better understanding of the inherited liability for neurodegenerative disease. Neuroimaging has proven valid both for the early diagnosis of neurodegenerative disorders [1, 2] , the noninvasive assessment of molecular and metabolic properties [39, 40] , and also as a measure of therapeutic target engagement [9] . Recently, inferences on progression of β-amyloid-associated cognitive decline have been made using magnetic resonance imaging of local susceptibility [41] . Jun Hua is an expert in clinical neuroimaging at Johns Hopkins University. He will provide particular expertise in the application of novel techniques allowing for the quantification of vascular and functional brain changes [42, 43] , which are frequent findings in early and preclinical AD and HD [1, 7] . Moreover, considering the impact of subcortical and hippocampal damage for the emergence of the clinical picture of various neurodegenerative disorders, a particular thematic focus will be set on neuroimaging approaches of this brain region, as established by Christine Tardif and her team at McGill University [44] [45] [46] . The standardized assessment of relevant brain changes and the investigation of their potential value for inferring on the progression of neurodegenerative disorder require novel and flexible data analysis strategies. Ender Konukoglu is an expert in mathematical and computational algorithms at ETH, and his expertise in biomedical image analysis has substantially contributed to recent advances in the prediction of individual disease courses and pathology [47] [48] [49] [50] .
We are well aware of the challenges ahead of us. Successful scientific work requires not only individual expertise, but also solid networks for a continuous exchange among the best researchers in the field and a platform where, in addition to conferences and personal communication, progress is documented for a wider interested and participating readership. Neurodegenerative Diseases will continue to be this sought-after platform, and all of us involved look forward to what promise to be fascinating developments aimed at freeing mankind of some of its most dreaded disease burdens.
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